Live Breaking News & Updates on Molnupiravir Capsules|Page 4
Stay updated with breaking news from Molnupiravir capsules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Domestic benchmark indices rose on Monday, tracking gains in ICICI Bank, Reliance Industries, Axis Bank and SBI, amid positive trends in global markets and hopes that surging coronavirus cases could peak soon and mitigate the pandemic s economic impact. Total Covid-19 cases in India surged over 3,50,000 on Sunday, a record jump in infections. However, analysts believe the current virus wave will not have an impact on the stock market similar to that of the first, lending some confidence to investors. Besides, the pick-up in pace of vaccination also aided the sentiment. Amid this backdrop, BSE barometer Sensex settled the day at 48,387, up 508 points. The index had gained as much as 790 points in the intra-day today. Meanwhile, NSE s Nifty50 index added 144 points to close at 14,485. ....
Natco Pharma seeks approval for phase-3 trial of antiviral drug Molnupiravir for COVID-19 treatment As per a press release from the Hyderabad-based company, pre-clinical data has proven that Molnupiravir has broad anti-influenza activity, comprising highly potent inhibition of SARS-CoV-2 replication BusinessToday.In | April 26, 2021 | Updated 12:30 IST Hyderabad-based drugmaker Natco Pharma is ready to launch the product this month if approval is given Drugmaker Natco Pharma Limited said on Monday that it has applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of phase-3 clinical trial of coronavirus antiviral drug Molnupiravir Capsules for the treatment of COVID-19 patients. The capsule has been developed by US pharma major Merck along with Ridgeback Biotherapeutics. As per a press release from the Hyderabad-based company, pre-clinical data has proven that Molnupiravir has broad anti-influenza activity, comprising highly potent in ....
Natco seeks emergency approval of Molnupiravir for COVID-19 treatment business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Natco Pharma seeks approval for Molnupiravir capsules for Covid-19 treatment PTI Hyderabad | Updated on American pharma major Merck along with Ridgeback Bio therapeutics has developed the drug Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients. American pharma major Merck along with Ridgeback Bio therapeutics has developed Molnupiravir(MK-4482). According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, it said. ....
Investors rushed to pick shares of Natco Pharma on the BSE on Monday as the firm sought Central Drugs Standard Control Organization s (CDSCO s) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients. At 11:30 am, shares of the pharmaceutical firm were ruling 5 per cent higher on the BSE, at Rs 923 apiece, as against a 1.4 per cent rise in the benchmark S&P BSE Sensex. In the intra-day deals, the shares surged 7.5 per cent to Rs 944 per share on the BSE. Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, the firm said in an exchange filing. ....